AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 281 min read$KIDS

Orthopediatrics outlines $270M-$273M 2026 revenue outlook while targeting $25M adjusted EBITDA and free cash flow breakeakeven or better (NASDAQ:KIDS)

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $72.7M, up 19% YoY. The company raised its full-year revenue guidance to $270M-$273M, a 14-16% increase. It also targets $25M adjusted EBITDA and free cash flow breakeven or better.

Original reporting
seekingalpha.com
Published Oct 28, 2026, 4:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 4:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$KIDS
Bullish
high confidence
Mentioned
$KIDS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$KIDSBullishHigh
01

Why it matters

The guidance upgrade provides a fresh data point for traders to reassess valuation.

02

Market read

Guidance lift is a primary catalyst for the stock, likely driving short‑term buying interest.

03

What to watch

Potential supply chain constraints or regulatory hurdles could temper the upside.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

OrthoPediatrics (NASDAQ:KIDS) reported record Q3 revenue and lifted its 2026 outlook.

Company-level read

Ticker impact

$KIDSBullishHigh confidence
Context

OrthoPediatrics raised full-year 2026 revenue guidance to $270M-$273M and targets $25M adjusted EBITDA, indicating stronger outlook.

Expected impact

likely upward pressure as investors price in higher revenue and profitability expectations

Evidence & confidence

The new revenue range and EBITDA target exceed prior expectations, providing a fresh catalyst for buying interest.

Market effects

Sector

Positive signal for pediatric healthcare and specialty device sector.

Regional

May boost sentiment for US small‑cap biotech/medical device stocks.

Global

Limited to niche market; no broad global effect.

Counterpoint

What could challenge this read

If the guidance is already priced in, the stock could face disappointment on execution risk.

Key entities

  • company
    OrthoPediatrics

    Pediatric medical device manufacturer

Read at source← All news

Also covered by

1 outlet

Related articles

OCT 28
$KIDSMed

OrthoPediatrics Corp (KIDS) (Q3 2026) Earnings Call Highlights: Record Revenue and Raised Guidance

OrthoPediatrics Corp (KIDS) reported Q3 2026 revenue growth and raised guidance, despite increased sales expenses and gross margin pressure. The company expects Q4 revenue of roughly $69 million, with CEO David Bailey noting a conservative approach to guidance. International growth was tempered by Brazil headwinds, and the company remains unprofitable with a GAAP net loss per share of $0.25.

finance.yahoo.com3 min
OCT 28
$KIDSMed

OrthoPediatrics Q3 Earnings Call Highlights

OrthoPediatrics (KIDS) reported Q3 revenue growth, with scoliosis revenue up 18% to $19.2M. The company surpassed 1,000 PNP tibial nail implantations and plans a full commercial release for PNP Retrograde in mid-2027. OPSB segment grew over 20%, with 60+ clinics. Gross margin remained at 74%, while GAAP net loss narrowed to $0.25 per share. The company raised full-year 2026 revenue guidance to $270M-$273M and expects positive free cash flow in 2027.

finance.yahoo.com2 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Q3 2026 Earnings Call Transcript

OrthoPediatrics (KIDS) reported Q3 2026 revenue of $727M, up 19% YoY, and raised full-year guidance to $270M-$273M. Growth was driven by legacy products, implant demand, and international sales. The company highlighted progress in its innovation super cycle, with new products like 3P Hip, Traxeo, and VerteGlide contributing to performance. Adjusted EBITDA and free cash flow were record highs, with plans to maintain positive cash flow in 2027.

finance.yahoo.com3 min
OCT 27
$KIDSHighAI 8/10

OrthoPediatrics receives FDA clearance for femur nail system

OrthoPediatrics (KIDS) received FDA clearance for its Pediatric Nailing Platform Femur Retrograde Nail System, designed for pediatric trauma and deformity correction. The system is available in diameters from 7 mm to 11 mm and will be released in 2026, with broader commercialization in 2027. The company has used its Pediatric Nailing Platform in approximately 15,000 patients worldwide.

investing.com2 min
OCT 27
$KIDSHigh

OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million…

ORTHOPEDIATRICS CORP (KIDS) filed an SEC Form 8-K — Results of Operations and Financial Condition. OrthoPediatrics Corp. Reports Third Quarter 2026 Financial Results and Increases 2026 Financial Guidance Record Third Quarter 2026 Revenue of $72.7 Million, Up 19% Year-over-Year WARSAW, Ind., October 27, 2026 -- OrthoPediatrics Corp. (“OrthoPediatrics” or the “Company”) (Nasdaq:

SEC EDGAR 8-K2 min
SEP 11
$KIDSHighAI 8/10

OrthoPediatrics (KIDS) Crosses $70M as Guidance Climbs Higher

OrthoPediatrics (KIDS) reported Q2 revenue of $70.5M, up 15% YoY, and raised 2026 guidance to $265M-$269M. Trauma and Deformity revenue grew 26%, while international sales rose 22%. Despite higher expenses, gross margin expanded to 74% and adjusted EBITDA doubled to $6.8M. Net loss remained at $7.2M, and cash reserves declined to $47.9M.

insidermonkey.com2 min